Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

    ... hypertension, smooth muscle dysfunction, and chronic hemolysis . Until recently, treatment was mainly supportive with most ...

    Research Article last updated 09/13/2016 - 1:53pm.

  2. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

    ... outcomes included the reduction of intravascular hemolysis , the change in hemoglobin (Hb) level, the withdrawal of ... overall survival. The effect of eculizumab on intravascular hemolysis was demonstrated by a reduction in lactate dehydrogenase ...

    Research Article last updated 08/15/2016 - 9:10am.

  3. Paroxysmal Nocturnal Hemoglobinuria: The Future Of Complement-Based Therapies

    ... clinical benefit, making C3-mediated extravascular hemolysis the next challenge of PNH treatment. Indeed, a number of novel ... in clinical benefit by preventing C3-mediated extravascular hemolysis. These second-generation complement inhibitors include anti-C3 ...

    Research Article last updated 08/15/2016 - 9:11am.

  4. Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?

    ...

    Research Article last updated 07/31/2012 - 12:44pm.

  5. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

    ... acquired disorder characterized by chronic intravascular hemolysis as the primary clinical manifestation and morbidities that ... platelets, resulting in complement-mediated intravascular hemolysis and other complications. Lysis of red blood cells is the most obvious ...

    Research Article last updated 05/14/2013 - 3:28pm.

  6. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

    ... C3, rendering such erythrocytes prone to extravascular hemolysis . This effect is associated with insufficient responsiveness seen ...

    Research Article last updated 04/29/2016 - 12:58pm.

  7. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study

    ... Intravascular hemolysis in Paroxysmal nocturnal hemoglobinuria (PNH) can ...

    Research Article last updated 04/29/2016 - 10:21am.

  8. Self-injected PNH therapy on the horizon

    ... percent inhibition (range 96 percent to 100 percent) of hemolysis at 24 hours. "The company's strategy and product profile appears ...

    Article last updated 07/07/2016 - 9:40am.

  9. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria

    ... that prevents complement-mediated intravascular hemolysis . However, a considerable fraction of PNH patients show ... we provide experimental evidence for such extravascular hemolysis and demonstrate that PNH erythrocytes from anti-C5-treated patients ...

    Research Article last updated 07/07/2015 - 2:14pm.

  10. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

    ... , she became pregnant. She developed breakthrough hemolysis at 20 weeks gestation. Pharmacokinetic and pharmacodynamic ... Escalation of her eculizumab dose successfully controlled hemolysis and restored therapeutic eculizumab level and activity. She ...

    Research Article last updated 06/23/2015 - 9:29am.